Tenofovir therapy for lamivudine resistance following liver transplantation

Annals of Pharmacotherapy

Volumn 38, Issue 12, 2004, Pages 1999-2004

  Neff, Guy W ^a   Nery, Jose ^b   Lau, Daryl T Y ^c   O'Brien, Christopher B ^b   Duncan, Robert ^d   Shire, Norah J ^e   Ruiz, Phillip ^d   Nery, Caio ^b   Montalbano, Marzia ^b   Muslu, Halim ^b   Safdar, Kamran ^b   Schiff, Eugene R ^b   Tzakis, Andreas G ^b   Madariaga, Juan R ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Adefovir; Hepatitis B virus; Hepatitis C virus; Lamivudine; Liver transplantation; Tenofovir disoproxil fumarate

Indexed keywords

ADEFOVIR; CREATININE; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LOBUCAVIR; TENOFOVIR; VIRUS DNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEROLOGY; TREATMENT OUTCOME; VIRUS REPLICATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 19944430564     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E280     Document Type: Article

References (13)

1. Castells L, Vargas V, Rodriguez F, Allende H, Buti M, Sanchez-Avila JF, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transplant 2002;8:892-900.
2. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
3. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Behalf of the Adefovir Dipovoxil Study 435 International Investigators G. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in preand post-liver transplantation patients. Hepatology 2003;38:1419-27.
4. Fragulidis GP, Cirocco RE, Weppler D, Berho M, Gillian G, Markou M, et al. In situ enzymatic oligonucleotide amplification of hepatitis C virus-RNA in liver biopsy specimens (reverse transcriptase in situ polymerase chain reaction) after orthotopic liver transplantation for hepatitis C-related liver disease. Transplantation 1998;66:1472-6.
5. Ben-Ari Z, Mor E, Manhaim V, Barak O, Bar-Nathan N, Shaharabani E, et al. Passive immunization with OMRI-Hep-B for prevention of hepatitis B virus reinfection after liver transplantation. Transplant Proc 2001;33:2895-6.
6. Nery JR, Weppler D, Lavandera R, Nery Avila C, Magill A, Rodriguez M, et al. Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Transplant Proc 1999;31:485-6.
7. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
8. van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation (letter). Gastroenterology 2003;124:586-7.
9. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-8.
10. Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. J Acquir Immune Defic Syndr 2003;34(suppl 1):S59-65.
11. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepatitis 2000;7:161-5.
12. Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 1993;8:353-7.
13. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant 2000;6:429-33.